Skip to main content
All lobbying filings

FRESENIUS KABI USA LLC

FRESENIUS KABI USA LLC filed a Q4 report for FRESENIUS KABI USA LLC on January 20, 2026.

Lobbying for FRESENIUS KABI USA LLC

All filings by FRESENIUS KABI USA LLC · Everything FRESENIUS KABI USA LLC has reported

 Filing · LD-2 quarterly report Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Expenses
$430,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Illinois

Official filing document

 Lobbyists on this filing 2
  • STU EVENHAUGEN New on this filing
    Previously held: Dir. of Pol. Analysis & Evaluation, Off. of the Assist. Sec. of Defense for Health Affairs; Strategy & Pol. Analyst, US Dept. of Health & Human Serv.; Sen. Risk Analyst, US Dept. of Homeland Sec.; Pol. Analyst, U.S. Dept. of Health & Human Services
  • CHRISTOPHER LEIBUNDGUTH New on this filing

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 11

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Medicare/Medicaid

Drug Shortages and Medicaid Specialty Drug Pharmacy Payment Reform

Health Issues

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act S. 1414/H.R._: Expedited Access to Biosimilars Act S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act US Drug Enforcement Administration Quota FDA/PTO Coordination USPTO Practices Most Favored Nation (MFN) Proposed Rule Biosimilar Tariffs Domestic Manufacturing Tariffs Medical Devices Generic Medicines Industry Net Effective Cost Biosimilar User Fee Act (BsUFA) Drug Shortages Domestic Manufacturing

Manufacturing

Domestic Manufacturing

Copyright/Patent/Trademark

PTAB Discretionary Denials

Trade (domestic/foreign)

Drug Shortages Domestic Manufacturing Tariffs Medical Devices Most Favored Nation (MFN) Proposed Rule Biosimilar Tariffs Generic Medicines

 Bills named in this filing 5

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem